Literature DB >> 29637237

[Three cases of severe chronic diarrhea with a rare cause and a simple therapy].

K-P Rommel1, E Schneider2, I Witschel3, U Halm4, M Zachäus4.   

Abstract

We report three cases of severe olmesartan-associated chronic diarrhea with weight loss and malassimilation syndrome. Histologically, a sprue-like enteropathy was diagnosed in each case, while serological tests for celiac disease were negative. After stopping the medication, symptoms improved within a few days. Histologically, remission was documented after 3 months. Olmesartan-associated enteropathy is an underestimated entity and an important differential diagnosis in patients with chronic diarrhea.

Entities:  

Keywords:  Angiotensin receptor blocker; Celiac disease, seronegative; Drug-related side effects and adverse reactions; Enteropathy; Olmesartan

Mesh：

Substances：

Year:  2018        PMID： 29637237     DOI： 10.1007/s00108-018-0417-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  17 in total

1.  Immunopathogenesis of olmesartan-associated enteropathy.

Authors:  E V Marietta; A M Nadeau; A K Cartee; I Singh; A Rishi; R S Choung; T-T Wu; A Rubio-Tapia; J A Murray
Journal:  Aliment Pharmacol Ther       Date:  2015-10-01       Impact factor: 8.171

2.  Olmesartan and intestinal adverse effects in the ROADMAP study.

Authors:  Jan Menne; Hermann Haller
Journal:  Mayo Clin Proc       Date:  2012-12       Impact factor: 7.616

3.  Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan.

Authors:  George Harrison Talbot
Journal:  Mayo Clin Proc       Date:  2012-12       Impact factor: 7.616

Review 4.  Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.

Authors:  Edmond C K Li; Balraj S Heran; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2014-08-22

Review 5.  Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology.

Authors:  Nina Burbure; Benjamin Lebwohl; Carolina Arguelles-Grande; Peter H R Green; Govind Bhagat; Stephen Lagana
Journal:  Hum Pathol       Date:  2015-12-19       Impact factor: 3.466

6.  Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers.

Authors:  Stephen M Lagana; Eric D Braunstein; Carolina Arguelles-Grande; Govind Bhagat; Peter H R Green; Benjamin Lebwohl
Journal:  J Clin Pathol       Date:  2014-10-23       Impact factor: 3.411

7.  Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan.

Authors:  M Zanelli; A Negro; R Santi; A Bisagni; M Ragazzi; S Ascani; L De Marco
Journal:  Aliment Pharmacol Ther       Date:  2017-08       Impact factor: 8.171

Review 8.  Olmesartan medoxomil.

Authors:  Gregory T Warner; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma.

Authors:  Marisa DeGaetani; Christina A Tennyson; Benjamin Lebwohl; Suzanne K Lewis; Hussein Abu Daya; Carolina Arguelles-Grande; Govind Bhagat; Peter H R Green
Journal:  Am J Gastroenterol       Date:  2013-05       Impact factor: 10.864

10.  Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

Authors:  E Imai; J C N Chan; S Ito; T Yamasaki; F Kobayashi; M Haneda; H Makino
Journal:  Diabetologia       Date:  2011-10-13       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.